ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Can tiny Dova take on Novartis? With its 2nd Doptelet nod and a price cut, maybe so
July 04, 2019In what one analyst team called Dova Pharmaceuticals’ “biggest catalyst to date,” the company won a second FDA nod for its platelet-boosting drug Doptelet, setting the stage for direct competition against Novartis and its still-growing blockbuster Promact -
Dova Pharmaceuticals Announces FDA Approval of Doptelet (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)
June 28, 2019Dova Pharmaceuticals Announces FDA Approval of Doptelet (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP).
Pharma Sources Insight January 2025
